<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05790655</url>
  </required_header>
  <id_info>
    <org_study_id>IORG0010499_202301</org_study_id>
    <nct_id>NCT05790655</nct_id>
  </id_info>
  <brief_title>Ovarian PRP for Diminished Ovarian Reserve</brief_title>
  <acronym>oPRP</acronym>
  <official_title>Ovarian Platelet-Rich Plasma Injections for Diminished Ovarian Reserve Patients: A Double-Blinded Placebo-Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Generation Next Fertility</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Igenomix</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Generation Next Fertility</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective double-blinded randomized placebo control study aims to determine if In&#xD;
      Vitro Fertilization (IVF) outcomes are improved by ovarian platelet-rich plasma injections&#xD;
      (oPRP) for women diagnosed with diminished ovarian reserve (DOR). Women with DOR notoriously&#xD;
      have the lowest chance of pregnancy and live birth compared to age-matched peers with a&#xD;
      normal or robust ovarian reserve.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo-controlled trial comparing ovarian injection of&#xD;
      platelet-rich plasma vs. placebo in women diagnosed with diminished ovarian reserve at risk&#xD;
      for a poor ovarian response (POR) between 35 to 42 years of age. Participants for this study&#xD;
      include patients who are planning to undergo IVF with preimplantation genetic testing for&#xD;
      aneuploidy (PGT-A) followed by a frozen embryo transfer (FET) cycle. Only patients with&#xD;
      either a euploid embryo or eligible mosaic embryo (following consultation with a geneticist),&#xD;
      as determined by PGT-A, will be allowed to proceed with a single blastocyst FET cycle&#xD;
&#xD;
      All patients will have a baseline ultrasound and blood work at the time of menses,&#xD;
      approximately one month prior to starting their initial IVF cycle. Routine monitoring will be&#xD;
      required to determine the day of ovulation. Once an LH surge is detected or if a lead&#xD;
      follicle on pelvic ultrasound is deemed large enough to induce ovulation, a &quot;trigger&quot; shot&#xD;
      with 250 mcg/0.5 mL of OvidrelÂ® will be self-administered subcutaneously (SQ). Based upon the&#xD;
      patient's randomization, either oPRP or ovarian Serum (oS) injections will be performed under&#xD;
      anesthesia and within 72 hours from the day of ovulation. Following their ovarian injections,&#xD;
      all patients will return for monitoring with the onset of menses approximately 14 to 16 days&#xD;
      from the date of ovulation.&#xD;
&#xD;
      A medication protocol will be determined at the start of each IVF cycle. Either a natural&#xD;
      (nIVF), mild (mIVF) or conventional (cIVF) IVF protocol will be chosen by the treating&#xD;
      physician. This determination will be based on findings from the repeat pelvic ultrasound&#xD;
      with AFC and blood work for anti-mullerian hormone (AMH), follicle stimulating hormone (FSH),&#xD;
      lutenizing hormone (LH), estradiol (E2), progesterone (P4), and beta-human chorionic&#xD;
      gonadotrophin (B-hCG). Natural IVF will be considered for patients with only 1-2 antral&#xD;
      follicles, mIVF for patients with 2-4 antral follicles observed, and cIVF for patients with&#xD;
      four or more antral follicles visualized at the time stimulation started.&#xD;
&#xD;
      Patients will begin their designated protocol and return four to five days following&#xD;
      medication start. A repeat pelvic ultrasound will be performed to measure the growth and size&#xD;
      of all follicles visualized along with the endometrial thickness. Also, blood work for E2,&#xD;
      FSH, LH, and P4 will be obtained. Monitoring for follicular and endometrial development will&#xD;
      continue routinely and as needed, until the majority of all follicles observed have a mean&#xD;
      diameter between 15 to 22 mm. Induction of ovulation will commence 35 and a half hours prior&#xD;
      to oocyte retrieval, by self-administration of 10,000 IU hCG SQ.&#xD;
&#xD;
      The patient will receive deep IV sedation anesthesia by a board-certified anesthesiologist&#xD;
      for her oocyte retrieval and placement of either her second oPRP or oS injections. Using&#xD;
      transvaginal ultrasound guidance, all follicles visualized under ultrasound will be aspirated&#xD;
      using standard practices by patients undergoing IVF at GNF. Aspirates will be collected in 10&#xD;
      ml test tubes. All oocytes will be assessed at the time of retrieval for maturity. All&#xD;
      oocytes that are deemed mature (MII) will undergo intracytoplasmic sperm injection (ICSI), to&#xD;
      maximize fertilization rates, 2-4 hours after identification of the first polar body. All&#xD;
      immature (non MII) oocytes will be isolated under a stereomicroscope and transferred into&#xD;
      maturation media and incubated further in a triple gas mixture (90% N2, 5% CO2, and 5% O2)&#xD;
      for up to 24 hours to allow maturation prior to ICSI. Following the oocyte retrieval, either&#xD;
      oPRP or oS will be performed as described previously.&#xD;
&#xD;
      Monitoring will recommence two weeks following the first oocyte retrieval to identify if any&#xD;
      residual follicles or ovarian cysts are present. If the ovaries are deemed resting and no&#xD;
      active ovarian cysts persist, then the patient will begin her second IVF cycle. Again, the&#xD;
      medication protocol will be determined by findings observed on pelvic ultrasound including&#xD;
      AFC and ovarian hormone testing. If the patient is deemed ineligible to start another IVF&#xD;
      cycle, then she will return with the following menstrual period to begin her second IVF&#xD;
      cycle. The process of monitoring patients, inducing ovulation and collecting oocytes will be&#xD;
      identical to the first oocyte retrieval. However, no additional oPRP or oS injections will be&#xD;
      performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, double-blinded placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The patient and PI will not know which arm the patient is in. This will not be unblinded until study completion</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>oPRP changes Ovarian Response and the total Number of oocytes retrieved</measure>
    <time_frame>12 months</time_frame>
    <description>Total oocyte yield</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oPRP impacts the Number or Euploid Embryos available for frozen embryo transfers</measure>
    <time_frame>12 months</time_frame>
    <description>Available embryos for frozen embryo transfers</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Diminished Ovarian Reserve</condition>
  <arm_group>
    <arm_group_label>oPRP injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients own prepared PRP will be injected into each ovary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient's serum will be injected into the ovary (not rich with platelets)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oPRP</intervention_name>
    <description>Prepared sample from patient's own blood collected and processed</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>oPRP injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of diminished ovarian reserve&#xD;
&#xD;
          -  Clinical diagnosis of poor ovarian response&#xD;
&#xD;
          -  Women age 35-42&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of premature ovarian failure&#xD;
&#xD;
          -  Clinical diagnosis of menopause.&#xD;
&#xD;
          -  Under 35 years of age&#xD;
&#xD;
          -  Over 42 years of age&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesse Hade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Generation Next Fertility</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alicia Broussard, PhD</last_name>
    <phone>3174456958</phone>
    <email>a.broussard@generationnextfertility.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jesse Hade, MD</last_name>
    <phone>2126410906</phone>
    <email>j.hade@generationnextfertility.com</email>
  </overall_contact_backup>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 6, 2023</study_first_submitted>
  <study_first_submitted_qc>March 16, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>March 16, 2023</last_update_submitted>
  <last_update_submitted_qc>March 16, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Platelet Rich Plasma</keyword>
  <keyword>DOR</keyword>
  <keyword>Ovarian PRP</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Collaboration to share protocol may be requested with PI</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>April 2023 to April 2024</ipd_time_frame>
    <ipd_access_criteria>Protocol may be shared with other research bodies upon request for collaboration</ipd_access_criteria>
    <ipd_url>http://www.generationnextfertility.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 16, 2023</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT05790655/Prot_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

